Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Valproate sodium added to low-dose cytarabine for elderly patients with AML non-M3
IRCT20240709062371N1Phase 2Completed
- Sponsor
- Shahid Beheshti University of Medical Sciences
- Start
- Mar 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of valproic acid and cytarabine in acute myeloid leukemia (AML) (2 arms), sponsored by Shahid Beheshti University of Medical Sciences. Primary endpoints: response rate to treatment, age and 8 more. Started Mar 2023; status: completed.
02
Drugs
valproic acidcytarabine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on IRCT20240709062371N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20240709062371N1.